Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2026 09:15 ET | Source: OPTIMI HEALTH CORP.

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

VANCOUVER, British Columbia, June 10, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical...
June 08, 2026 08:00 ET | Source: OPTIMI HEALTH CORP.

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD,...
June 08, 2026 04:00 ET | Source: Alvotech

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
June 08, 2026 04:00 ET | Source: Alvotech

Matvæla- og lyfjastofnun Bandaríkjanna tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir AVT16, fyrirhugaða hliðstæðu við Entyvio

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefði tekið til umsagnar og afgreiðslu umsókn um markaðsleyfi í Bandaríkjunum fyrir AVT16, fyrirhugaða...
June 04, 2026 04:00 ET | Source: Alvotech

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

REYKJAVIK, Iceland, June 4, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
June 04, 2026 04:00 ET | Source: Alvotech

Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea

Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að fyrirtækið hafi lagt inn að nýju til Matvæla- og lyfjastofnunar Bandaríkjanna (FDA) umsóknir um leyfi til markaðssetningar í Bandaríkjunum á...
June 03, 2026 16:30 ET | Source: Alvotech

Main Results of 2026 Annual and Extraordinary General Meeting

REYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House,...
June 02, 2026 16:30 ET | Source: Alvotech

Alvotech to present at upcoming investor conferences in June

REYKJAVIK, ICELAND (June 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...
June 02, 2026 16:30 ET | Source: Alvotech

Alvotech tekur þátt í þremur fjárfestaráðstefnum í Bandaríkjunum í júní

REYKJAVÍK 2. JÚNÍ 2026 – Alvotech tekur þátt í þremur fjárfestaráðstefnum í Bandaríkjunum fyrri hluta júnímánaðar. Þar munu Róbert Wessman, stjórnarformaður Alvotech og Balaji V. Prasad,...
June 02, 2026 07:30 ET | Source: OPTIMI HEALTH CORP.

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United...